TG Therapeutics, Inc. (NASDAQ:TGTX) Strengthens Profitability; Near-Term Momentum Shows Caution

TG Therapeutics registers improving operating profitability alongside robust liquidity, while near-term technicals signal potential momentum fatigue. The balance between strong fundamentals and technical warning signs should shape short-term price behavior.

Technical Analysis

ADX & Directional Indicators: ADX at 48.57 indicates a very strong trend environment. DI+ peaked and reversed, which signals bearish directional pressure, while DI- has fallen, which reads as a bullish development; those offsetting directional signals, combined with a high ADX, imply a forceful shift may follow the recent peak.

MACD: MACD sits at 1.31 with a signal line at 1.08, so MACD currently trades above its signal line; however, the MACD trend shows a peak-and-reversal, which signals bearish momentum despite the recent crossing above the signal line.

MRO: MRO at 28.68 places price above the oscillator’s target and therefore indicates likely downward pressure on the price from a momentum regression perspective.

RSI & Momentum: RSI at 56.42 and rising indicates bullish internals without overbought conditions, leaving room for continuation but not eliminating risk of a pullback given other indicators.

Price Relative to Moving Averages & Bands: Latest close at $36.50 sits above the 12-day EMA ($35.71 rising), the 20-day average ($35.51), and the 200-day average ($34.52), which reflects positive medium- and long-term price placement. Price trades just below the 1x upper Bollinger band ($37.15), signaling proximity to the short-term upper volatility band while the SuperTrend lower sits near $34.37 as a nearby technical floor.

 


Fundamental Analysis

Profitability: EBIT comes in at $37,636,000 and EBIT margin registers 26.66%. That EBIT margin reads above the industry peer mean of -0.76% and above the industry peer median of 0.24%, which places operating profitability well ahead of typical peers.

Revenue & Growth: Total revenue equals $141,148,000. Quarter-over-quarter revenue growth measures 43.36%, while year-over-year revenue growth registers 6.66%, showing a strong recent sequential acceleration alongside modest annual expansion.

Margins and Cash Generation: Gross margin remains high at 86.58% with a slight YoY decline of 2.38%. Operating margin records 24.69% with QoQ and YoY improvements. Operating cash flow sits at $7,436,000 and free cash flow at $7,394,000, yielding a free cash flow yield of roughly 0.14%, which signals limited conversion of market value into cash returns despite positive operating cash flow generation.

Earnings: Reported EPS equals $0.17 versus an estimate of $0.29, producing an EPS surprise ratio of -41.38%, which reflects a meaningful shortfall relative to consensus estimates for the reported period.

Liquidity & Capital Structure: Cash and short-term investments total $251,870,000 and cash alone reaches $129,126,000. Current ratio stands at 3.86, slightly below the industry peer mean of 3.93 but above typical working-capital adequacy thresholds. Debt-to-equity registers 91.78%, which reads above the industry peer mean of 24.1% and indicates a higher leverage profile relative to peers; debt-to-EBITDA measures about 6.73.

Returns: Return on equity measures 10.20% and return on assets 4.15%, both positive and improving QoQ; earnings growth displays a quarterly contraction but annual improvement relative to certain prior periods.

Valuation: Price-to-earnings ratio stands at about 216.15 and forward P/E near 151.08, while price-to-book registers 18.67. WMDST values the stock as over-valued. Those multiples, combined with a low free cash flow yield, frame a stretched valuation relative to cash-generation metrics without invoking any sector-level comparison.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-04
NEXT REPORT DATE: 2025-11-03
CASH FLOW  Begin Period Cash Flow 133.4 M
 Operating Cash Flow 7.4 M
 Capital Expenditures -42.00 K
 Change In Working Capital -36.74 M
 Dividends Paid
 Cash Flow Delta -3.00 M
 End Period Cash Flow 130.4 M
 
INCOME STATEMENT REVENUE
 Total Revenue 141.1 M
 Forward Revenue 48.0 M
COSTS
 Cost Of Revenue 18.9 M
 Depreciation 59.0 K
 Depreciation and Amortization 59.0 K
 Research and Development 31.8 M
 Total Operating Expenses 106.3 M
PROFITABILITY
 Gross Profit 122.2 M
 EBITDA 37.7 M
 EBIT 37.6 M
 Operating Income 34.8 M
 Interest Income
 Interest Expense 6.7 M
 Net Interest Income -6.72 M
 Income Before Tax 30.9 M
 Tax Provision 2.7 M
 Tax Rate 8.8 %
 Net Income 28.2 M
 Net Income From Continuing Operations 28.2 M
EARNINGS
 EPS Estimate 0.29
 EPS Actual 0.17
 EPS Difference -0.12
 EPS Surprise -41.379 %
 Forward EPS 0.24
 
BALANCE SHEET ASSETS
 Total Assets 702.6 M
 Intangible Assets
 Net Tangible Assets 276.4 M
 Total Current Assets 664.0 M
 Cash and Short-Term Investments 251.9 M
 Cash 129.1 M
 Net Receivables 231.5 M
 Inventory 155.2 M
 Long-Term Investments 3.3 M
LIABILITIES
 Accounts Payable
 Short-Term Debt
 Total Current Liabilities 171.9 M
 Net Debt 115.9 M
 Total Debt 253.7 M
 Total Liabilities 426.2 M
EQUITY
 Total Equity 276.4 M
 Retained Earnings -1.50 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 1.75
 Shares Outstanding 158.025 M
 Revenue Per-Share 0.89
VALUATION
 Market Capitalization 5.2 B
 Enterprise Value 5.2 B
 Enterprise Multiple 136.989
Enterprise Multiple QoQ -71.002 %
Enterprise Multiple YoY -44.609 %
Enterprise Multiple IPRWA TGTX: 136.989
high: 47.216
median: 14.143
mean: 5.404
low: -68.907
 EV/R 36.584
CAPITAL STRUCTURE
 Asset To Equity 2.542
 Asset To Liability 1.649
 Debt To Capital 0.479
 Debt To Assets 0.361
Debt To Assets QoQ 2541.551 %
Debt To Assets YoY 5446.851 %
Debt To Assets IPRWA high: 0.995
TGTX: 0.361
mean: 0.186
median: 0.062
low: 0.0
 Debt To Equity 0.918
Debt To Equity QoQ 2326.17 %
Debt To Equity YoY 6139.429 %
Debt To Equity IPRWA high: 1.577
TGTX: 0.918
mean: 0.241
median: 0.059
low: -1.039
PRICE-BASED VALUATION
 Price To Book (P/B) 18.674
Price To Book QoQ -25.212 %
Price To Book YoY 16.912 %
Price To Book IPRWA TGTX: 18.674
high: 16.592
median: 6.295
mean: 5.276
low: -10.064
 Price To Earnings (P/E) 216.151
Price To Earnings QoQ -82.689 %
Price To Earnings YoY -52.8 %
Price To Earnings IPRWA TGTX: 216.151
high: 44.732
mean: -11.202
median: -19.0
low: -73.374
 PE/G Ratio 0.463
 Price To Sales (P/S) 36.571
Price To Sales QoQ -25.401 %
Price To Sales YoY -5.269 %
Price To Sales IPRWA high: 517.227
mean: 56.358
TGTX: 36.571
median: 19.711
low: 0.25
FORWARD MULTIPLES
Forward P/E 151.083
Forward PE/G 0.324
Forward P/S 107.502
EFFICIENCY OPERATIONAL
 Operating Leverage 12.38
ASSET & SALES
 Asset Turnover Ratio 0.208
Asset Turnover Ratio QoQ 6.057 %
Asset Turnover Ratio YoY 9.478 %
Asset Turnover Ratio IPRWA high: 0.388
TGTX: 0.208
mean: 0.115
median: 0.113
low: -0.001
 Receivables Turnover 0.67
Receivables Turnover Ratio QoQ -11.555 %
Receivables Turnover Ratio YoY -32.292 %
Receivables Turnover Ratio IPRWA high: 6.517
median: 1.422
mean: 1.413
TGTX: 0.67
low: 0.012
 Inventory Turnover 0.121
Inventory Turnover Ratio QoQ 4.436 %
Inventory Turnover Ratio YoY 15.831 %
Inventory Turnover Ratio IPRWA high: 2.946
mean: 0.608
median: 0.434
TGTX: 0.121
low: 0.006
 Days Sales Outstanding (DSO) 136.291
CASH CYCLE
 Cash Conversion Cycle Days (CCC)
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.287
 CapEx To Revenue -0.0
 CapEx To Depreciation -0.712
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 521.5 M
 Net Invested Capital 521.5 M
 Invested Capital 521.5 M
 Net Tangible Assets 276.4 M
 Net Working Capital 492.1 M
LIQUIDITY
 Cash Ratio 1.465
 Current Ratio 3.863
Current Ratio QoQ -3.982 %
Current Ratio YoY 7.861 %
Current Ratio IPRWA high: 25.128
mean: 3.929
TGTX: 3.863
median: 2.52
low: 0.021
 Quick Ratio 2.96
Quick Ratio QoQ -2.581 %
Quick Ratio YoY 4.456 %
Quick Ratio IPRWA high: 14.041
mean: 2.968
TGTX: 2.96
median: 2.158
low: 0.021
COVERAGE & LEVERAGE
 Debt To EBITDA 6.731
 Cost Of Debt 2.413 %
 Interest Coverage Ratio 5.604
Interest Coverage Ratio QoQ 209.741 %
Interest Coverage Ratio YoY 111.691 %
Interest Coverage Ratio IPRWA high: 940.414
mean: 44.685
TGTX: 5.604
median: 2.347
low: -1580.294
 Operating Cash Flow Ratio -0.062
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO)
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 6.993 %
 Revenue Growth 16.79 %
Revenue Growth QoQ 43.357 %
Revenue Growth YoY 6.657 %
Revenue Growth IPRWA high: 269.352 %
mean: 20.427 %
TGTX: 16.79 %
median: 12.272 %
low: -259.856 %
 Earnings Growth 466.667 %
Earnings Growth QoQ -683.334 %
Earnings Growth YoY -396.97 %
Earnings Growth IPRWA TGTX: 466.667 %
high: 155.0 %
mean: 14.879 %
median: 11.33 %
low: -175.0 %
MARGINS
 Gross Margin 86.583 %
Gross Margin QoQ -0.64 %
Gross Margin YoY -2.383 %
Gross Margin IPRWA high: 100.0 %
TGTX: 86.583 %
median: 80.103 %
mean: 77.784 %
low: -77.751 %
 EBIT Margin 26.664 %
EBIT Margin QoQ 163.609 %
EBIT Margin YoY 86.071 %
EBIT Margin IPRWA high: 338.783 %
TGTX: 26.664 %
median: 23.755 %
mean: -75.684 %
low: -5123.44 %
 Return On Sales (ROS) 24.685 %
Return On Sales QoQ 144.043 %
Return On Sales YoY 72.261 %
Return On Sales IPRWA high: 89.247 %
median: 28.85 %
TGTX: 24.685 %
mean: -79.507 %
low: -5698.0 %
CASH FLOW
 Free Cash Flow (FCF) 7.4 M
 Free Cash Flow Yield 0.143 %
Free Cash Flow Yield QoQ -129.485 %
Free Cash Flow Yield YoY -26.667 %
Free Cash Flow Yield IPRWA high: 36.371 %
median: 0.516 %
TGTX: 0.143 %
mean: -0.341 %
low: -74.318 %
 Free Cash Growth -125.727 %
Free Cash Growth QoQ -1148.249 %
Free Cash Growth YoY -24.919 %
Free Cash Growth IPRWA high: 157.51 %
median: 13.562 %
mean: 4.37 %
TGTX: -125.727 %
low: -183.577 %
 Free Cash To Net Income 0.262
 Cash Flow Margin -7.504 %
 Cash Flow To Earnings -0.376
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 4.147 %
Return On Assets QoQ 405.732 %
Return On Assets YoY 133.502 %
Return On Assets IPRWA high: 36.544 %
TGTX: 4.147 %
median: 1.616 %
mean: -1.419 %
low: -68.545 %
 Return On Capital Employed (ROCE) 7.091 %
 Return On Equity (ROE) 0.102
Return On Equity QoQ 378.283 %
Return On Equity YoY 163.216 %
Return On Equity IPRWA high: 1.117
TGTX: 0.102
median: 0.04
mean: 0.007
low: -1.572
 DuPont ROE 10.974 %
 Return On Invested Capital (ROIC) 6.579 %
Return On Invested Capital QoQ 37.982 %
Return On Invested Capital YoY -269.781 %
Return On Invested Capital IPRWA high: 53.785 %
TGTX: 6.579 %
median: 3.175 %
mean: 1.459 %
low: -71.959 %

Six-Week Outlook

Near-term technicals favor consolidation or a controlled pullback: MACD’s peak-and-reversal and a positive MRO suggest downward pressure, while RSI and price above key moving averages retain momentum support. Strong ADX amplifies the significance of any directional move. Liquidity and solid margins reduce business risk, but elevated valuation and a negative EPS surprise increase sensitivity to further execution headlines. For swing horizons, expect price to oscillate around short-term averages with downside testing more likely than a fresh breakout until momentum indicators re-accelerate in a bullish direction.

About TG Therapeutics, Inc.

TG Therapeutics, Inc. (NASDAQ:TGTX) develops and commercializes innovative treatments targeting B-cell mediated diseases. Headquartered in Morrisville, North Carolina, the company actively addresses unmet medical needs in the field of immunology and oncology. TG Therapeutics markets BRIUMVI, an anti-CD20 monoclonal antibody designed for adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company’s robust development pipeline includes Umbralisib, an oral PI3K-delta inhibitor aimed at treating relapsed or refractory marginal zone lymphoma and follicular lymphoma. Additionally, TG-1701, a covalently bound Bruton’s tyrosine kinase (BTK) inhibitor, exhibits selectivity for BTK in vitro. TG-1801, a bispecific CD47 and CD19 antibody, further exemplifies their commitment to advancing therapeutic options. TG Therapeutics collaborates with various partners, including LFB Biotechnologies S.A.S., Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S.A., to enhance their research and commercialization efforts. The company also engages in a collaboration agreement with Checkpoint Therapeutics, Inc. for anti-PD-L1 and anti-GITR antibody research in hematological malignancies. Established in 1993, TG Therapeutics continues to drive progress in biopharmaceutical innovation.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.